130676-64-1 Usage
Uses
Used in Pharmaceutical Industry:
Orlistat Impurity is used as a reference material for the development and validation of analytical methods in the pharmaceutical industry. It helps in the identification, quantification, and quality control of Orlistat in drug products, ensuring the safety and efficacy of the medication.
Used in Research and Development:
Orlistat Impurity is utilized as a research compound in the field of drug development. It aids scientists in understanding the chemical properties, stability, and potential side effects of Orlistat, which can contribute to the improvement of the drug or the development of new medications with similar therapeutic effects.
Used in Quality Control and Regulatory Compliance:
Orlistat Impurity is employed as a tool for quality control and regulatory compliance in the pharmaceutical sector. It assists in the assessment of the manufacturing process, ensuring that the final drug product meets the required standards and guidelines set by regulatory authorities.
Check Digit Verification of cas no
The CAS Registry Mumber 130676-64-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,6,7 and 6 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 130676-64:
(8*1)+(7*3)+(6*0)+(5*6)+(4*7)+(3*6)+(2*6)+(1*4)=121
121 % 10 = 1
So 130676-64-1 is a valid CAS Registry Number.
InChI:InChI=1/C22H40O2/c1-3-5-7-9-10-11-12-13-15-17-21-19-18-20(22(23)24-21)16-14-8-6-4-2/h18,21H,3-17,19H2,1-2H3/t21-/m0/s1
130676-64-1Relevant articles and documents
Tetrahydrolipstatin: Thermal and hydrolytic degradation
Stalder,Schneider,Oesterhelt
, p. 1022 - 1036 (2007/10/02)
The thermal and hydrolytic degradation of tetrahydrolipstatin (THL, 1) was investigated. All main degradation products were isolated, characterized, and synthesized. Labile intermediates unavailable to isolation were detected and identified by GC/MS analysis of their silylated derivatives, and whenever possible, compared with independently prepared reference compounds. The identified degradation products represent at least 97% of the total degradation mixture. Two main reaction pathways are proposed. Pharmacological data are reported for the degradation mixture and the main degradation products.
